Timrepigene emparvovec

N/A

Report date: 2025/12/02 20:00:12

Base Information

Drug NameTimrepigene emparvovec
Drug Alias NameAAV-REP1 - NightstaRx表达REP1的重组腺相关病毒表达REP1基因重组腺相关病毒Recombinant adeno-associated virus expressing REP1AAV-REP1 gene therapy +[10] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionRab escort protein 1 stimulantsGene transference
TargetsRab escort protein 1
Therapy Area/IndicationsChoroideremiaRetinal Dysplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of OxfordBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of AlbertaUniversity Of Oxford
Inactive CompaniesBiogen Inc
Active IndicationsChoroideremia
Inactive IndicationsRetinal Dysplasia

Other Information

ATC CodeN/A
Related LinksN/A